SNY - Sanofi • Financials

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	46,007	12,590	-	13%	2.4	81,848	7%	8,492	0.67	11,052	-3,212	-8,901	7,840	-656	-4,986	84%	4%
12/2024	46,083	11,278	-	13%	2.3	80,651	7%	8,906	0.79	9,160	-3,325	-5,997	5,835	-314	-4,934	85%	4.1%
12/2025	54,810	14,105	-	17%	3.7	83,743	11%	12,827	0.91	12,245	-4,151	-9,629	8,094	-5,902	-5,643	62%	4.8%

To see all financials—including updated, you must be Premium.